12-month persistence with F/TAF-based regimens is high in the real world

A real-world study of treatment-naïve (TN) and treatment-experienced (TE) adults with HIV infection suggests that emtricitabine/tenofovir alafenamide (F/TAF) – based antiretroviral regimens are associated with a high rate of persistence and low rate of discontinuation.1,2